Published in PLoS One on October 07, 2016
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem (1976) 903.81
The biology of VEGF and its receptors. Nat Med (2003) 32.13
The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol (1991) 5.61
A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J (1996) 5.33
Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev (2002) 5.15
Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem (1992) 4.92
A thioredoxin gene fusion expression system that circumvents inclusion body formation in the E. coli cytoplasm. Biotechnology (N Y) (1993) 4.49
Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A (1998) 4.48
The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell (1993) 4.33
Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med (1999) 4.33
Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol (2005) 4.03
Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci U S A (1991) 3.95
Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest (2002) 3.70
The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation (2003) 3.45
The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem (1996) 2.75
Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci U S A (1996) 2.71
Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol (2007) 2.69
Growth factor delivery-based tissue engineering: general approaches and a review of recent developments. J R Soc Interface (2010) 2.69
Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. Circulation (2000) 2.05
Thioredoxin-1 (Trx1) engineered mesenchymal stem cell therapy increased pro-angiogenic factors, reduced fibrosis and improved heart function in the infarcted rat myocardium. Int J Cardiol (2015) 2.04
Human studies of angiogenic gene therapy. Circ Res (2009) 1.92
Covalently conjugated VEGF--fibrin matrices for endothelialization. J Control Release (2001) 1.74
Soluble VEGF isoforms are essential for establishing epiphyseal vascularization and regulating chondrocyte development and survival. J Clin Invest (2004) 1.72
A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther (2002) 1.63
Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action. Mol Biol Cell (2010) 1.49
Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int J Cancer (1998) 1.48
Solubility of proteins isolated from inclusion bodies is enhanced by fusion to maltose-binding protein or thioredoxin. Protein Expr Purif (1998) 1.40
Gene fusion expression systems in Escherichia coli. Curr Opin Biotechnol (1995) 1.32
The emerging role of the thioredoxin system in angiogenesis. Arterioscler Thromb Vasc Biol (2010) 1.18
Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism. Cell Growth Differ (1995) 1.13
VEGF-A mRNA processing, stability and translation: a paradigm for intricate regulation of gene expression at the post-transcriptional level. Nucleic Acids Res (2013) 1.11
Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning. Cytokine Growth Factor Rev (2013) 1.05
Improvement in the expression of CYP2B6 by co-expression with molecular chaperones GroES/EL in Escherichia coli. Protein Expr Purif (2005) 1.01
New prospects in the roles of the C-terminal domains of VEGF-A and their cooperation for ligand binding, cellular signaling and vessels formation. Angiogenesis (2012) 0.97
Purification and characterization of heterologously expressed nitrilases from filamentous fungi. Appl Microbiol Biotechnol (2011) 0.92
Bimodal concentration-dependent effect of thrombin on endothelial cell proliferation and growth factor release in culture. J Surg Res (2001) 0.91
Overexpression and characterization of a glucose-tolerant β-glucosidase from T. aotearoense with high specific activity for cellobiose. Appl Microbiol Biotechnol (2015) 0.89
Nanofibrous poly(lactide-co-glycolide) membranes loaded with diamond nanoparticles as promising substrates for bone tissue engineering. Int J Nanomedicine (2012) 0.87
Overexpression in Escherichia coli and purification of human fibroblast growth factor (FGF-2). Biochemistry (Mosc) (2009) 0.87
Vascular endothelial growth factor-delivery systems for cardiac repair: an overview. Theranostics (2012) 0.87
Functionally active VEGF fusion proteins. Protein Expr Purif (2001) 0.87
Effects of co-expression of molecular chaperones on heterologous soluble expression of the cold-active lipase Lip-948. Protein Expr Purif (2011) 0.87
Characterization and optimization of vascular endothelial growth factor(165) (rhVEGF(165)) expression in Escherichia coli. Protein Expr Purif (2012) 0.86
Targeting the intragraft microenvironment and the development of chronic allograft rejection. Hum Immunol (2012) 0.85
Folding screening assayed by proteolysis: application to various cystine deletion mutants of vascular endothelial growth factor. Protein Eng (2001) 0.85
Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates. Vaccine (2010) 0.85
The novel Fh8 and H fusion partners for soluble protein expression in Escherichia coli: a comparison with the traditional gene fusion technology. Appl Microbiol Biotechnol (2012) 0.84
Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. results of the CENTAURO antigen dose escalation phase I clinical trial. Vaccine (2014) 0.84
Overexpression of biologically active VEGF121 fusion proteins in Escherichia coli. J Biotechnol (2006) 0.84
Endothelial cells exhibit differential chemokinetic and mitogenic responsiveness to alpha-thrombin. J Surg Res (1997) 0.84
Prokaryotic expression, refolding, and purification of functional human vascular endothelial growth factor isoform 165: purification procedures and refolding conditions revisited. Protein Expr Purif (2010) 0.83
Application of recombinant thioredoxin1 for treatment of heart disease. J Mol Cell Cardiol (2010) 0.83
Solubility of disulfide-bonded proteins in the cytoplasm of Escherichia coli and its "oxidizing" mutant. World J Gastroenterol (2005) 0.83
High-yield expression of human vascular endothelial growth factor VEGF(165) in Escherichia coli and purification for therapeutic applications. Protein Expr Purif (2010) 0.83
Expression and purification of functional human vascular endothelial growth factor-a121; the most important angiogenesis factor. Adv Pharm Bull (2014) 0.82
Mineralized poly(lactic acid) scaffolds loading vascular endothelial growth factor and the in vivo performance in rat subcutaneous model. J Biomed Mater Res A (2012) 0.82
Roles of vascular endothelial growth factor in acute rejection reaction following liver transplantation. Transpl Immunol (2011) 0.81
Thioredoxin and hematologic malignancies. Adv Cancer Res (2014) 0.80
Heterologous expression, chaperone mediated solubilization and purification of parasitic nematode-specific growth factor-like protein of Setaria digitata. Asian Pac J Trop Med (2014) 0.80
Purification and refolding of vascular endothelial growth factor-B. Protein Sci (2000) 0.80
Functional expression of single-chain Fv antibody in the cytoplasm of Escherichia coli by thioredoxin fusion and co-expression of molecular chaperones. Protein Expr Purif (2009) 0.80
Biologically active vascular endothelial growth factor as a bacterial recombinant glutathione S-transferase fusion protein. Biotechnol Appl Biochem (2006) 0.80
Coexpression of molecular chaperones to enhance functional expression of anti-BNP scFv in the cytoplasm of Escherichia coli for the detection of B-type natriuretic peptide. World J Microbiol Biotechnol (2010) 0.79
Heparin and Vascular Endothelial Growth Factor Loaded Poly(L-lactide-co-caprolactone) Nanofiber Covered Stent-Graft for Aneurysm Treatment. J Biomed Nanotechnol (2015) 0.78
Experimental studies of a vaccine formulation of recombinant human VEGF antigen with aluminum phosphate. Hum Vaccin Immunother (2015) 0.77
Construction of extracellular microenvironment to improve surface endothelialization of NiTi alloy substrate. Mater Sci Eng C Mater Biol Appl (2015) 0.76
Refolding and purification of recombinant human VEGF-121 expressed as inclusion bodies in Escherichia coli. Nan Fang Yi Ke Da Xue Xue Bao (2006) 0.76